Epcoritamab

Multispecific antibody

Also known as GEN3013

Approvedregulatory verdict

Evidence outlook

Approved: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (3)
JP
  • Relapsed or refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, FL3B) after two or more lines of systemic therapy
Product first approved 2023tipranks.com
EU
  • Monotherapy for adults with relapsed or refractory DLBCL after two or more lines of systemic therapy (conditional marketing authorisation, TEPKINLY)
Product first approved 2023tipranks.com
CA
  • In combination with lenalidomide and rituximab for adults with relapsed/refractory grade 1, 2, or 3a follicular lymphoma (Notice of Compliance, reported 2026-09-24)
cancernetwork.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Diffuse Large B-Cell Lymphoma
NCT07226752 · Genmab
2022-10-08 – 2028-06-14 · Diffuse Large B-Cell Lymphoma
What this study did
Follicular Lymphoma
Phase 2 (40)
Diffuse Large B-Cell Lymphoma
NCT06287398 · Australasian Leukaemia and Lymphoma Group
2023-12-11 – 2031-11 · DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Large Cell Lymphoma, Relapsed, Follicular Large Cell Lymphoma
What this study did
NCT07814001 · The Lymphoma Academic Research Organisation
2026-12 – 2031-05 · Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Follicular Lymphoma Grade 3B
What this study did
NCT06919939 · University of Miami
2026-01-07 – 2031-01-07 · Large B-cell Lymphoma, Relapse, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma
What this study did
NCT06238648 · Academic and Community Cancer Research United
2024-01-31 – 2030-12-31 · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT06905509 · University of California, Davis
2025-07-31 – 2030-08-01 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT07097363 · University of Washington
2025-12-07 – 2030-05-31 · B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
What this study did
NCT07197307 · Universität Münster
2025-10-31 – 2030-04-30 · Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
What this study did
NCT06931652 · The Lymphoma Academic Research Organisation
2025-09-22 – 2030-01 · Primary CNS Lymphoma (PCNSL)
What this study did
NCT07365306 · City of Hope Medical Center
2026-07-27 – 2029-10-15 · Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT07588698 · Carrie Ho, MD
2026-11-15 – 2029-08-31 · Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
NCT06458439 · Abramson Cancer Center at Penn Medicine
2024-09-24 – 2027-12 · Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT07451652 · Hospital Universitario Dr. Jose E. Gonzalez
2026-03-17 – 2027-09 · Relapsed/Refractory Diffuse Large B Cell Lymphoma
What this study did
NCT05660967 · Genmab
2023-03-06 – 2026-06-10 · Diffuse Large B-Cell Lymphoma
What this study did
NCT07030699 · Memorial Sloan Kettering Cancer Center
2025-08-13 – 2026-03-31 · Lymphoma
What this study did
Follicular Lymphoma
NCT06563596 · Reid Merryman, MD
2025-01-21 – 2032-03-01 · Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
What this study did
NCT05848765 · University of Birmingham
2023-09-04 – 2031-11-30 · Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT07783594 · M.D. Anderson Cancer Center
2027-02-12 – 2030-12-31 · Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma
What this study did
NCT05783609 · Reid Merryman, MD
2023-06-21 – 2030-02 · Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
What this study did
NCT06510361 · Beth Israel Deaconess Medical Center
2024-11-20 – 2028-08-01 · Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
What this study did
NCT06575686 · City of Hope Medical Center
2025-03-11 – 2028-07-16 · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
What this study did
NCT06112847 · City of Hope Medical Center
2024-01-24 – 2027-08-10 · Follicular Lymphoma
What this study did
Large B-Cell Lymphoma
NCT07126236 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2025-08-04 – 2031-12-27 · Large B Cell Lymphoma
What this study did
NCT06723457 · Reem Karmali
2025-07-25 – 2029-02-18 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
What this study did
NCT05852717 · Vijendra Singh
2023-10-31 – 2028-11-24 · Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
What this study did
NCT06811272 · Massachusetts General Hospital
2025-06-05 – 2028-10-01 · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
What this study did
NCT06414148 · Peter MacCallum Cancer Centre, Australia
2024-05-14 – 2028-05 · Relapsed/Refractory Large B-cell Lymphoma
What this study did
Other / comorbidity
NCT07882173 · National Heart, Lung, and Blood Institute (NHLBI)
2026-11-24 – 2033-11-01 · Waldenstrom Macroglobulinemia
What this study did
NCT07662928 · AIDS Malignancy Consortium
2026-09-16 – 2033-04-30 · Adult Burkitt Lymphoma
What this study did
NCT07860775 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2026-09-15 – 2032-10-15 · CLL / SLL
What this study did
NCT07819214 · University of California, Irvine
2026-12 – 2032-10 · CLL, CLL (Chronic Lymphocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), BTKi
What this study did
NCT07738887 · The Lymphoma Academic Research Organisation
2026-12-31 – 2032-06-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06796998 · Izidore Lossos, MD
2025-10-13 – 2031-04-15 · Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
What this study did
NCT07917780 · German CLL Study Group
2026-06-18 – 2030-05-15 · Richter Transformation
What this study did
NCT07883135 · National Research Center for Hematology, Russia
2026-09 – 2029-08-01 · Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma
What this study did
NCT07108998 · Zulfa Omer
2025-08-22 – 2029-07-01 · CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant, Chronic Lymphocytic Leukemia Variants
What this study did
NCT07218510 · City of Hope Medical Center
2026-01-07 – 2029-06-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06510491 · Gottfried von Keudell, MD PhD
2024-12-06 – 2027-12-31 · Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder
What this study did
Phase 1/2 (10)
Diffuse Large B-Cell Lymphoma
NCT06536049 · Yazeed Sawalha
2025-04-02 – 2027-10-31 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
What this study did
NCT04663347 · Genmab
2020-11-03 – 2027-09-30 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
What this study did
NCT04542824 · Genmab
2020-08-20 – 2027-09 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT04358458 · Genmab
2020-03-13 – 2023-07-28 · Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
What this study did
High-Grade B-Cell Lymphoma
Other / comorbidity
NCT07283679 · M.D. Anderson Cancer Center
2026-02-24 – 2033-09-30 · Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
What this study did
NCT05791409 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-04-15 – 2032-12 · CLL/SLL
What this study did
NCT06090539 · Bristol-Myers Squibb
2023-12-29 – 2028-10-28 · Relapsed/Refractory Non-Hodgkin Lymphoma
What this study did
NCT04623541 · Genmab
2020-11-25 – 2028-02 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
What this study did
Phase 1 (7)
Diffuse Large B-Cell Lymphoma
NCT07714421 · Jonsson Comprehensive Cancer Center
2026-12-08 – 2031-10-08 · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT07528352 · University of Utah
2026-06-01 – 2031-06 · Diffuse Large B Cell Lymphoma
What this study did
NCT06672705 · Timothy Voorhees
2025-06-16 – 2026-12-31 · Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
What this study did
Other / comorbidity
NCT06447376 · Taylor Brooks
2025-01-14 – 2028-09-01 · Non-Hodgkin Lymphoma, Cytokine Release Syndrome
What this study did
NCT07082868 · Memorial Sloan Kettering Cancer Center
2025-08-13 – 2028-08 · Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
What this study did
NCT06676033 · National Heart, Lung, and Blood Institute (NHLBI)
2025-07-18 – 2027-07-01 · Leukemia, Chronic Lymphocytic, Richter Syndrome
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Diffuse Large B-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Epcoritamab: this drugApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
AcalabrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
IbrutinibPhase 3Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Purinostat MesylatePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
SHR-A1912Phase 3Antibody–drug conjugateCD79bnot yet gradedNo reviewed efficacy summary in this indication
Zilovertamab VedotinPhase 2/3Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary in this indication
AZD5492
Phase 1/2(overall)
Multispecific antibodyCD20 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
CND261
Phase 1(overall)
Biologic (subtype unspecified)CD20 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
Plamotamab
Phase 1(overall)
Multispecific antibodyCD20 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(55 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Epcoritamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2026-11 · NCT06287398 · CT.gov ↗
What to watch
December 2026 (1)
Phase 1Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06672705 · CT.gov ↗
What to watch
2027 (17)
February 2027 (1)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-02-18 · NCT06723457 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-03 · NCT05451810 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative DisorderRecruiting
Est. primary completion 2027-04-30 · NCT06510491 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-05-01 · NCT06510361 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT05578976 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Leukemia, Chronic Lymphocytic, Richter SyndromeActive not recruiting
Est. primary completion 2027-07-01 · NCT06676033 · CT.gov ↗
What to watch
Phase 2CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant …Recruiting
Est. primary completion 2027-07-01 · NCT07108998 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Follicular LymphomaActive not recruiting
Est. primary completion 2027-08-10 · NCT06112847 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06536049 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1/2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-09 · NCT07451652 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1/2B-Cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10 · NCT05201248 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-10 · NCT06458439 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-28 · NCT06090539 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-11-24 · NCT05852717 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …Active not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
2028 (14)
January 2028 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-01 · NCT06931652 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-02 · NCT05783609 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-07 · NCT07814001 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-07-01 · NCT06905509 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06045247 · CT.gov ↗
What to watch
August 2028 (2)
Phase 1Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma …Recruiting
Est. primary completion 2028-08 · NCT07082868 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07588698 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Non-Hodgkin Lymphoma, Cytokine Release SyndromeRecruiting
Est. primary completion 2028-09-01 · NCT06447376 · CT.gov ↗
What to watch
October 2028 (3)
Phase 2CLL, CLL (Chronic Lymphocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), BTKiNot yet recruiting
Est. primary completion 2028-10 · NCT07819214 · CT.gov ↗
What to watch
Phase 2Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell LymphomaRecruiting
Est. primary completion 2028-10-01 · NCT07883135 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma …Recruiting
Est. primary completion 2028-10-15 · NCT06796998 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Non-hodgkin LymphomaActive not recruiting
Est. primary completion 2028-11 · NCT05206357 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07783594 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Phase 1/2Large B-Cell LymphomaActive not recruiting
Est. primary completion 2029-01 · NCT03625037 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2CLL/SLLRecruiting
Est. primary completion 2029-03 · NCT05791409 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-05-31 · NCT05848765 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaRecruiting
Est. primary completion 2029-06-08 · NCT07218510 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-10-15 · NCT07365306 · CT.gov ↗
What to watch
December 2029 (3)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT06238648 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07738887 · CT.gov ↗
What to watch
2030 (8)
March 2030 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2030-03-01 · NCT06563596 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2030-04-30 · NCT07197307 · CT.gov ↗
What to watch
May 2030 (2)
Phase 2Richter TransformationRecruiting
Est. primary completion 2030-05-15 · NCT07917780 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2030-05-31 · NCT07097363 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2030-06 · NCT07528352 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2030-10-08 · NCT07714421 · CT.gov ↗
What to watch
Phase 2CLL / SLLNot yet recruiting
Est. primary completion 2030-10-15 · NCT07860775 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2030-11-01 · NCT07882173 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2031-01-07 · NCT06919939 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2Adult Burkitt LymphomaRecruiting
Est. primary completion 2031-05-30 · NCT07662928 · CT.gov ↗
What to watch
September 2031 (1)
Phase 1/2Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2031-09-30 · NCT07283679 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2031-12-27 · NCT07126236 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026Topline resultPhase 3 EPCORE DLBCL-2 positive topline results
July 2026ApprovalEuropean Commission approves Tepkinly with lenalidomide and rituximab in R/R follicular lymphoma
EU, European Commission · Source ↗
June 2026Topline resultPhase 3 EPCORE DLBCL-4 met its progression-free survival primary endpoint
16 January 2026Topline resultEPCORE DLBCL-1 phase 3 topline
Genmab · Source ↗
18 November 2025ApprovalFDA approves EPKINLY + R2 for relapsed/refractory follicular lymphoma
US, FDA · Source ↗